<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004181</url>
  </required_header>
  <id_info>
    <org_study_id>NU 92H3T</org_study_id>
    <secondary_id>NU-92H3T</secondary_id>
    <secondary_id>NCI-G99-1639</secondary_id>
    <nct_id>NCT00004181</nct_id>
  </id_info>
  <brief_title>Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia</brief_title>
  <official_title>Allogeneic Bone Marrow Transplantation for Patients With Chronic Myelogenous Leukemia in the Chronic Phase or Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Bone marrow transplantation may be able to replace immune cells that were&#xD;
      destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of allogeneic bone marrow transplantation&#xD;
      in treating patients who have multiple myeloma, chronic phase chronic myelogenous leukemia,&#xD;
      or agnogenic myeloid metaplasia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of allogeneic bone marrow transplantation (BMT) following&#xD;
           high-dose cyclophosphamide and total body irradiation in patients with multiple myeloma,&#xD;
           agnogenic myeloid metaplasia, or chronic myelogenous leukemia in first or second chronic&#xD;
           phase.&#xD;
&#xD;
        -  Determine the efficacy of BMT following busulfan and cyclophosphamide in these patients.&#xD;
&#xD;
        -  Determine the toxic effects of these preparative regimens in these patients.&#xD;
&#xD;
      OUTLINE: Patients are stratified by remission (first vs second vs third).&#xD;
&#xD;
      Patients who have not undergone prior radiotherapy receive cyclophosphamide IV on days -6 and&#xD;
      -5 and then undergo total body irradiation twice a day on days -4 to -1. Allogeneic bone&#xD;
      marrow is infused on day 0.&#xD;
&#xD;
      Patients who have undergone prior radiotherapy receive oral busulfan every 6 hours on days -7&#xD;
      to -4 or -6 to -3 and cyclophosphamide IV over 2 hours on days -3 and -2. Allogeneic bone&#xD;
      marrow is infused on day 0.&#xD;
&#xD;
      Patients are followed at days 30 and 90, at 6 months, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20-30 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <completion_date type="Actual">August 2004</completion_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Cytologically proven disease of one of the following types with transfusion-dependent&#xD;
             anemia or thrombocytopenia (less than 50,000/mm^3):&#xD;
&#xD;
               -  Multiple myeloma&#xD;
&#xD;
               -  Agnogenic myeloid metaplasia&#xD;
&#xD;
               -  Chronic myelogenous leukemia in first or second chronic phase&#xD;
&#xD;
                    -  Philadelphia chromosome with BCR gene rearrangement&#xD;
&#xD;
          -  Suitable sibling bone marrow donor available&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  15 to physiologic 55&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0 or 1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  SGOT less than 2 times normal&#xD;
&#xD;
          -  Alkaline phosphatase less than 2 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 2 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Ejection fraction normal by MUGA&#xD;
&#xD;
          -  No acute myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No active angina pectoris&#xD;
&#xD;
          -  No active congestive heart failure&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  FEV greater than 50% predicted&#xD;
&#xD;
          -  DLCO at least 50%&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No concurrent organ damage or medical problems that would preclude therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin S. Tallman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>January 21, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <disposition_first_submitted>February 16, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>February 16, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 18, 2011</disposition_first_posted>
  <last_update_submitted>June 8, 2012</last_update_submitted>
  <last_update_submitted_qc>June 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>chronic idiopathic myelofibrosis</keyword>
  <keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

